Sanofi Scores Clinical Win In Sixth Disease For Dupixent
First Biologic To Reduce Itch And Skin Lesions From Prurigo Nodularis
The French major and partner Regeneron expect to file Dupixent for the rare skin disease next year after a Phase III trial of the blockbuster hit its primary and secondary endpoints.
